Further prospective clinical trials examining the usefulness of CYFRA 21‐1 as an effective method for identifying K19+ HCC patients and for assessing the therapeutic efficacy of TGFβ receptor 1 inhibitors in K19+ HCC patients will advance the clinical application of K19+ HCC‐CSCs. Here, KRT19 is linked to hepatocellular carcinoma.